These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29337686)

  • 1. Forgotten public health impacts of cancer - an overview.
    Viegas S; Ladeira C; Costa-Veiga A; Perelman J; Gajski G
    Arh Hig Rada Toksikol; 2017 Dec; 68(4):287-297. PubMed ID: 29337686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative cancer therapies: putting costs into context.
    Khayat D
    Cancer; 2012 May; 118(9):2367-71. PubMed ID: 21918962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost and burden of cancer in the European Union 1995-2014.
    Jönsson B; Hofmarcher T; Lindgren P; Wilking N
    Eur J Cancer; 2016 Oct; 66():162-70. PubMed ID: 27589247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden of Bladder Cancer Across the European Union.
    Leal J; Luengo-Fernandez R; Sullivan R; Witjes JA
    Eur Urol; 2016 Mar; 69(3):438-47. PubMed ID: 26508308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect costs of diabetes and its impact on the public finance: the case of Poland.
    Torój A; Mela A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):93-105. PubMed ID: 28796563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'It was a big monetary cut'-A qualitative study on financial toxicity analysing patients' experiences with cancer costs in Germany.
    Lueckmann SL; Schumann N; Hoffmann L; Roick J; Kowalski C; Dragano N; Richter M
    Health Soc Care Community; 2020 May; 28(3):771-780. PubMed ID: 31802578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.
    Carrera PM; Kantarjian HM; Blinder VS
    CA Cancer J Clin; 2018 Mar; 68(2):153-165. PubMed ID: 29338071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The public health implications of asthma.
    Bousquet J; Bousquet PJ; Godard P; Daures JP
    Bull World Health Organ; 2005 Jul; 83(7):548-54. PubMed ID: 16175830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Innovative therapy, early and cost-benefit assessment].
    Dierks C
    Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
    [No Abstract]   [Full Text] [Related]  

  • 13. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.
    Sherman EJ; Pfister DG; Ruchlin HS; Rubin DM; Radzyner MH; Kelleher GH; Slovin SF; Kelly WK; Scher HI
    Cancer; 2001 Feb; 91(4):841-53. PubMed ID: 11241254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of in-patient cancer chemotherapy at a tertiary care hospital.
    Wani MA; Tabish SA; Jan FA; Khan NA; Wafai ZA; Pandita KK
    J Cancer Res Ther; 2013; 9(3):397-401. PubMed ID: 24125973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How Long Should We Continue the Chemotherapy?-From the View Point of Health Economics].
    Koinuma N
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):809-18. PubMed ID: 27431625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bending the Cost Curve in Childhood Cancer.
    Russell H; Bernhardt MB
    Curr Hematol Malig Rep; 2016 Aug; 11(4):295-302. PubMed ID: 27193602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial Burden of Cancer Drug Treatment in Lebanon.
    Elias F; Khuri FR; Adib SM; Karam R; Harb H; Awar M; Zalloua P; Ammar W
    Asian Pac J Cancer Prev; 2016; 17(7):3173-7. PubMed ID: 27509947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessing the economic impact of cancer in Chile: a direct and indirect cost measurement based on 2009 registries].
    Cid C; Herrera C; Rodríguez R; Bastías G; Jiménez J
    Medwave; 2016 Aug; 16(7):e6509. PubMed ID: 27532152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic burden of cancer in Korea in 2002.
    Kim SG; Hahm MI; Choi KS; Seung NY; Shin HR; Park EC
    Eur J Cancer Care (Engl); 2008 Mar; 17(2):136-44. PubMed ID: 18302650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.